Wyeth Nutritionals: Pfizer’s New MVP, Or Benchwarmer?
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth appears confident its nutritionals business will continue to grow because it is investing in new R&D facilities, mainly in emerging markets where sales opportunities are spiking.
You may also be interested in...
Pfizer’s New Org Chart Brings Eight Wyeth Execs Topside
In a move designed to allay concerns about post-Wyeth integration challenges, Pfizer outlined on April 7 the leadership structure of the future entity
Pfizer’s New Org Chart Brings Eight Wyeth Execs Topside
In a move designed to allay concerns about post-Wyeth integration challenges, Pfizer outlined on April 7 the leadership structure of the future entity
Pfizer Drafts A New “Org Chart” Post Wyeth Merger
Pfizer to appoint a number of key Wyeth execs to prominent positions post-merger, sending a clear signal that it is handling the integration of Wyeth differently from its previous acquisitions of Pharmacia and Warner Lambert.